GlobeNewswire

Shorter GMAT Exam Launches on April 16

Dela
Candidate-Friendly Change Designed to Enhance Test-Taking Experience
 
RESTON, Va., April 04, 2018 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC) is shortening the length of the GMAT exam by 30 minutes as part of its ongoing focus on creating the best possible testing experience and offering user-friendly features. The new, shorter exam - 3.5 hours instead of 4 - will be available for test-takers worldwide beginning April 16. 

The quality of the exam remains unchanged in terms of reliability, validity, security and integrity. GMAT scores before and after this change will be the same and comparable across time.

"We are always looking for ways to help build candidate confidence and streamline the test experience, all with one goal in mind-to help GMAT test-takers do their very best on exam day," said Vineet Chhabra, senior director of product management for GMAC. "We believe candidates will have less anxiety and feel better prepared, which can contribute to a better reflection of their true performance on the exam."

The time savings are achieved by streamlining the two longer sections of the exam, the Quantitative and Verbal Reasoning sections, reducing the number of unscored, research questions in these sections. Several tutorial and instruction screens that test-takers see at the test center have also been simplified. There are no changes to the exam's Analytical Writing or Integrated Reasoning sections. The way the GMAT exam is scored, the content of the exam, the question types and the average time per question are not changing.

"Through our ongoing market feedback and operational reviews, we were able to identify this opportunity to shorten the exam, without changing its reliability," said Chhabra. "This change will not affect GMAT exam scoring as the number of scored questions will not change. The scoring algorithm will be the same; the Total Score and individual Quantitative and Verbal section scores will be comparable to the exams taken prior to this change. There is no action or change required on the part of business schools and universities. We are providing candidates with a better testing experience, while providing business schools with the same high quality, fair and reliable scores."

Along with these changes, GMAC is providing a new, online tutorial that mimics the screens that test-takers see on exam day, further enhancing and streamlining the test center experience. By moving the tutorial information online, to www.mba.com/, test takers can access it prior to arriving at the test center, at their convenience and as often as they wish.

The GMAT exam is designed to showcase the skills that are most relevant to the world's leading graduate business programs; 9 out of 10 new MBA enrollments globally are made using a GMAT score. 

To align with the changes, GMAC is launching new GMAT Official Prep tools to match the structure of the shorter exam. The GMAT Official Practice Exams and Practice Questions will be available on an online platform for better ease-of-use, as well as some feature improvements such as single sign-on and ability to access prep materials across multiple devices. GMAT Official Prep tools are the only official source of retired GMAT questions, and the Council's research shows that candidates who use official products score an average of 18 percent higher on the GMAT exam than those who don't. The updated practice tools will be available by the end of April.    

These changes are part of a series of candidate-friendly enhancements to the GMAT exam in recent years, all focused on improving the testing experience, including: 

  • Exam section order selection at the testing center (Select Section Order)
  • Making unofficial scores available immediately, before leaving the test center following the exam
  • Updates to score cancellation and reinstatement options

To learn more about these changes, please review our FAQs: http://www.mba.com/global/frequently-asked-questions/shorter-gmat-exam

About GMAC: The Graduate Management Admission Council (GMAC) is a global, non-profit association of 223 leading graduate business schools. Founded in 1953, we are actively committed to advancing the art and science of admissions by convening and representing the industry and offering best-in-class products and services for schools and students. GMAC owns and administers the Graduate Management Admission Test® (GMAT®) exam, used by more than 7,000 graduate programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive MBA programs around the world. The Council is based in the United States with offices in London, New Delhi (Gurugram), and Hong Kong. For information on assessments, study tools and services for candidates, visit www.mba.com. For information about The Council and our market intelligence, professional development opportunities and services for graduate management education, please visit www.gmac.com.

MEDIA CONTACT: Tania Hernandez-Andersen, GMAC Sr. Dir. of Corporate Brand Communications, thernandez-andersen@gmac.com or 703-668-9638 (office), 571-294-4059 (mobile).




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum